Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer

Russ P. Carstens, James V. Eaton, Hannah R. Krigman, Philip J. Walther, Mariano Garcia-Blanco

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Progression of prostate cancer from an androgen sensitive to androgen insensitive tumor has previously been shown to be accompanied by a change in alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in a rat model of prostate cancer. This change results in loss of the FGF-R2(IIIb) isoform and predominant expression of the FGF-R2(IIIc) isoform. We sought to determine whether this change in FGF-R2 splicing is also associated with androgen insensitivity in human prostate tumors. We analysed three well characterized human prostate cancer cell lines and three metastatic prostate tumors which have been maintained as xenografts in nude mice. One of the cell lines, LNCaP, and two of the xenografts, DUKAP-1 and DUKAP-2, have been characterized as androgen sensitive, whereas two of the cell lines, DU-145 and PC-3, and one of the xenografts, DU9479, display androgen independent growth. Using an RT-PCR based assay, we demonstrated that progressive loss of the FGF-R2(IIIb) isoform correlated with androgen insensitivity in these human prostate cancer models. These findings lend support to the hypothesis that that loss of FGF-RZ(IIIb) may be one step in a series of events which lead to progression of human prostate cancer.

Original languageEnglish (US)
Pages (from-to)3059-3065
Number of pages7
JournalOncogene
Volume15
Issue number25
StatePublished - Dec 18 1997
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 2
Alternative Splicing
Androgens
Prostatic Neoplasms
Heterografts
Protein Isoforms
Cell Line
Prostate
Neoplasms
Nude Mice
human FGFR2 protein
Polymerase Chain Reaction
Growth

Keywords

  • Alternative splicing
  • Androgen sensitivity
  • Fibroblast growth factor receptors
  • Prostate cancer
  • Xenograft cell lines

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Carstens, R. P., Eaton, J. V., Krigman, H. R., Walther, P. J., & Garcia-Blanco, M. (1997). Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene, 15(25), 3059-3065.

Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. / Carstens, Russ P.; Eaton, James V.; Krigman, Hannah R.; Walther, Philip J.; Garcia-Blanco, Mariano.

In: Oncogene, Vol. 15, No. 25, 18.12.1997, p. 3059-3065.

Research output: Contribution to journalArticle

Carstens, RP, Eaton, JV, Krigman, HR, Walther, PJ & Garcia-Blanco, M 1997, 'Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer', Oncogene, vol. 15, no. 25, pp. 3059-3065.
Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco M. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene. 1997 Dec 18;15(25):3059-3065.
Carstens, Russ P. ; Eaton, James V. ; Krigman, Hannah R. ; Walther, Philip J. ; Garcia-Blanco, Mariano. / Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. In: Oncogene. 1997 ; Vol. 15, No. 25. pp. 3059-3065.
@article{1f675918194749d4a26dafbd0242cc57,
title = "Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer",
abstract = "Progression of prostate cancer from an androgen sensitive to androgen insensitive tumor has previously been shown to be accompanied by a change in alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in a rat model of prostate cancer. This change results in loss of the FGF-R2(IIIb) isoform and predominant expression of the FGF-R2(IIIc) isoform. We sought to determine whether this change in FGF-R2 splicing is also associated with androgen insensitivity in human prostate tumors. We analysed three well characterized human prostate cancer cell lines and three metastatic prostate tumors which have been maintained as xenografts in nude mice. One of the cell lines, LNCaP, and two of the xenografts, DUKAP-1 and DUKAP-2, have been characterized as androgen sensitive, whereas two of the cell lines, DU-145 and PC-3, and one of the xenografts, DU9479, display androgen independent growth. Using an RT-PCR based assay, we demonstrated that progressive loss of the FGF-R2(IIIb) isoform correlated with androgen insensitivity in these human prostate cancer models. These findings lend support to the hypothesis that that loss of FGF-RZ(IIIb) may be one step in a series of events which lead to progression of human prostate cancer.",
keywords = "Alternative splicing, Androgen sensitivity, Fibroblast growth factor receptors, Prostate cancer, Xenograft cell lines",
author = "Carstens, {Russ P.} and Eaton, {James V.} and Krigman, {Hannah R.} and Walther, {Philip J.} and Mariano Garcia-Blanco",
year = "1997",
month = "12",
day = "18",
language = "English (US)",
volume = "15",
pages = "3059--3065",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "25",

}

TY - JOUR

T1 - Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer

AU - Carstens, Russ P.

AU - Eaton, James V.

AU - Krigman, Hannah R.

AU - Walther, Philip J.

AU - Garcia-Blanco, Mariano

PY - 1997/12/18

Y1 - 1997/12/18

N2 - Progression of prostate cancer from an androgen sensitive to androgen insensitive tumor has previously been shown to be accompanied by a change in alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in a rat model of prostate cancer. This change results in loss of the FGF-R2(IIIb) isoform and predominant expression of the FGF-R2(IIIc) isoform. We sought to determine whether this change in FGF-R2 splicing is also associated with androgen insensitivity in human prostate tumors. We analysed three well characterized human prostate cancer cell lines and three metastatic prostate tumors which have been maintained as xenografts in nude mice. One of the cell lines, LNCaP, and two of the xenografts, DUKAP-1 and DUKAP-2, have been characterized as androgen sensitive, whereas two of the cell lines, DU-145 and PC-3, and one of the xenografts, DU9479, display androgen independent growth. Using an RT-PCR based assay, we demonstrated that progressive loss of the FGF-R2(IIIb) isoform correlated with androgen insensitivity in these human prostate cancer models. These findings lend support to the hypothesis that that loss of FGF-RZ(IIIb) may be one step in a series of events which lead to progression of human prostate cancer.

AB - Progression of prostate cancer from an androgen sensitive to androgen insensitive tumor has previously been shown to be accompanied by a change in alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in a rat model of prostate cancer. This change results in loss of the FGF-R2(IIIb) isoform and predominant expression of the FGF-R2(IIIc) isoform. We sought to determine whether this change in FGF-R2 splicing is also associated with androgen insensitivity in human prostate tumors. We analysed three well characterized human prostate cancer cell lines and three metastatic prostate tumors which have been maintained as xenografts in nude mice. One of the cell lines, LNCaP, and two of the xenografts, DUKAP-1 and DUKAP-2, have been characterized as androgen sensitive, whereas two of the cell lines, DU-145 and PC-3, and one of the xenografts, DU9479, display androgen independent growth. Using an RT-PCR based assay, we demonstrated that progressive loss of the FGF-R2(IIIb) isoform correlated with androgen insensitivity in these human prostate cancer models. These findings lend support to the hypothesis that that loss of FGF-RZ(IIIb) may be one step in a series of events which lead to progression of human prostate cancer.

KW - Alternative splicing

KW - Androgen sensitivity

KW - Fibroblast growth factor receptors

KW - Prostate cancer

KW - Xenograft cell lines

UR - http://www.scopus.com/inward/record.url?scp=0031577732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031577732&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 3059

EP - 3065

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 25

ER -